Maor Shlomo

881 posts

Maor Shlomo banner
Maor Shlomo

Maor Shlomo

@MS_BASE44

Founder @base44

Tel Aviv, Israel Katılım Ekim 2024
193 Takip Edilen16K Takipçiler
Sabitlenmiş Tweet
Maor Shlomo
Maor Shlomo@MS_BASE44·
We’re introducing a new model benchmark. And it’s a different kind of benchmark. (Basemark? Vibench?) A different kind because it’s breathing, constantly updated from millions of builders. Not a closed set of tasks. For a while now the public benchmark have not been really useful. Many models scoring high on benchmarks with very low real world usability So we’re introducing to the world a new benchmark that we’re using internally and found extremely useful. Our benchmark is basically how satisfied millions of users are when using different models. IMO it’s the closest measurement to how useful a model is in real world use cases. This metric is also correlated with our own business metrics - conversion, retention, etc. We called it the frustration meter. It’s automatically analysing millions of messages daily It detects bug loops, repeated requests, etc. We use this to benchmark every model we consider shipping. Not by asking "did it generate correct code." By asking "how did the builder feel after using it." it’s a good benchmark to measure model degradation. So far in the past few weeks we haven’t found any. Here's where the top models stand right now, ranked by average frustration score (scale 1 to 5, lower is better): opus 4.6 - 1.3 sonnet 4.6 - 1.4 opus 4.7 - 1.5 gpt 5.5 - 1.5 gpt 5.4 - 1.6 Gemini 3.1 - 2.2 For app building, Opus 4.6 seems better than 4.7 to a lot of builders. We ran Opus 4.7 50/50 against Opus 4.6 across over 10,000 apps. Frustration riseed by 43%. Turns per request by 19%. Gemini 3.1 don’t perform well at the moment, I left out of the graph as it made it unclear due to it’s rapid changes in this benchmark. Quick note - this is all aggregated data, and do not involve reading individual or identifiable conversations. We’ll keep tracking it and I’ll share it from time to time.
Maor Shlomo tweet media
English
25
18
298
26.1K
weisser
weisser@julianweisser·
@MS_BASE44 > Opus 4.6 seems better than 4.7 to a lot of builders. you posted this minutes after I sent this to solo founders gc
weisser tweet media
English
2
0
5
883
Maor Shlomo
Maor Shlomo@MS_BASE44·
We’re introducing a new model benchmark. And it’s a different kind of benchmark. (Basemark? Vibench?) A different kind because it’s breathing, constantly updated from millions of builders. Not a closed set of tasks. For a while now the public benchmark have not been really useful. Many models scoring high on benchmarks with very low real world usability So we’re introducing to the world a new benchmark that we’re using internally and found extremely useful. Our benchmark is basically how satisfied millions of users are when using different models. IMO it’s the closest measurement to how useful a model is in real world use cases. This metric is also correlated with our own business metrics - conversion, retention, etc. We called it the frustration meter. It’s automatically analysing millions of messages daily It detects bug loops, repeated requests, etc. We use this to benchmark every model we consider shipping. Not by asking "did it generate correct code." By asking "how did the builder feel after using it." it’s a good benchmark to measure model degradation. So far in the past few weeks we haven’t found any. Here's where the top models stand right now, ranked by average frustration score (scale 1 to 5, lower is better): opus 4.6 - 1.3 sonnet 4.6 - 1.4 opus 4.7 - 1.5 gpt 5.5 - 1.5 gpt 5.4 - 1.6 Gemini 3.1 - 2.2 For app building, Opus 4.6 seems better than 4.7 to a lot of builders. We ran Opus 4.7 50/50 against Opus 4.6 across over 10,000 apps. Frustration riseed by 43%. Turns per request by 19%. Gemini 3.1 don’t perform well at the moment, I left out of the graph as it made it unclear due to it’s rapid changes in this benchmark. Quick note - this is all aggregated data, and do not involve reading individual or identifiable conversations. We’ll keep tracking it and I’ll share it from time to time.
Maor Shlomo tweet media
English
25
18
298
26.1K
Maor Shlomo
Maor Shlomo@MS_BASE44·
Introducing Base44 Platform Migrations! You can now move any project from other platforms into Base44 in 2 clicks. For those of you who are tired of paying for Salesforce / HubSpot / Shopify / Wordpress / etc - A few clicks and Base44 will create a clone of your instance, that you can own and customize. Connect your account from a growing number of integrations - Base44 will build your interface / website / app - and clone your data into your new creation. This is something i’m very excited about as we’re helping businesses transition into a more customer-friendly SaaS environment. Eager to hear your ideas on how to use it - Drop your use case below. Best ones get $1,000 in credits from me.
Base44@Base44

Introducing: Base44’s new platform migration feature. If your needs have outgrown your current software, you can now bring your projects from other platforms into Base44 in a single click. This includes your Salesforce pipeline, Shopify catalog or WordPress site. Also whatever you’ve built on Lovable, Bolt, or Replit. To celebrate the launch, anyone who completes migration by May 5th, 12am ET gets 25 free credits added to their account!

English
25
12
363
73.1K
Maor Shlomo
Maor Shlomo@MS_BASE44·
Just shipped: SEO & GEO for your @Base44 apps. You can now run a full scan, get a scored breakdown, and fix everything with AI. No SEO background needed. Two things get scored separately: - SEO: how Google finds you - meta tags, crawlability, structured data, content quality - GEO: how AI tools find you - ChatGPT, Gemini, Perplexity. Different logic than Google. What ranks on one doesn't automatically work on the other. There are millions of builders on Base44. Most of them ship something real and then it just sits there. Someone searches for exactly the tool they built - on Google or inside ChatGPT - and gets nothing. That's what this solves. One thing worth knowing specifically: we now generate llms.txt automatically. It's a file that tells AI search engines what your app does and how to reference it. If a user asks ChatGPT for "best app to manage X" and you built it, you now have a shot at showing up. It scans your app and shows you exactly what's missing: a meta description on your pricing page, structured data that Google expects, an image for when someone shares the link. You click Fix with AI, it writes them for you. Live for all builders now. Under the new Growth section.
Maor Shlomo tweet media
English
24
13
146
14.3K
Maor Shlomo
Maor Shlomo@MS_BASE44·
@petergyang Try out our superagents Would love to get your feedback and would love to show you around
English
1
0
6
742
Peter Yang
Peter Yang@petergyang·
A great personal agent should: 1. Get work done across email, calendar, Google Workspace, or any API/MCP it's hooked up to 2. Act proactively and reliably (e.g., cron jobs, triggers, follow-ups) 3. Have excellent memory that helps it "just get you" over time 4. Work across web and mobile without slash commands or manual setup 5. Let you switch between text, voice, video, and live calling mid-conversation 6. Be reachable from any 3rd party messaging app, just like a real person 7. Have a personality that makes it fun to talk to OpenClaw, Claude Code, Codex - the truth is that none of them check all these boxes yet.
English
141
48
722
92K
Base44
Base44@Base44·
Peter is building a climbing training app with one superagent as his entire team:
Base44 tweet media
English
7
7
38
4.7K
Maor Shlomo retweetledi
Base44
Base44@Base44·
Base44 is now live inside @claudeai. Create and manage apps without leaving your workflow.
English
14
18
145
13.6K
Base44
Base44@Base44·
It’s 4.4 aka Base44 Day! Not an official holiday, but we’ll take it Today, we’re celebrating the builders, creators, and teams who make our community what it is. So we wanted to give something back: 44% off Builder, Pro & Elite annual plans 44 referral credits for you and your +1 Happy 4.4! 🧡
Base44 tweet media
English
19
13
73
7.7K
Maor Shlomo
Maor Shlomo@MS_BASE44·
@Base44 Happy 4.4 day for those who celebrate !
English
1
0
12
451
Fran Guillén
Fran Guillén@dokproject·
@MS_BASE44 Checkout PlusVitech. We are repurposing a drug for cancer treatment with our new formulation. We are getting complete remissions in terminal patients in different types of cancer. Now starting phase 1/2 clinical trial in lung cancer. We are closing a new investment round. DM pls
English
1
0
0
328
Maor Shlomo
Maor Shlomo@MS_BASE44·
I'm looking to invest in cancer research and breakthrough treatment companies Cancer is humanity's worst enemy, and unfortunately, it's one of the few frontier problems i don't see getting solved in the next 2-3 years.  I'll be able to write checks up to a few million (usually up to a million).  I will work extremely hard to help the founders. I'll leverage my network as much as possible to overcome bureaucracies and help hunt down talent for every company I'm investing in. Things I'm particularly interested in:  1. Accelerating clinical trials: As AI gets smarter and allows novel hypotheses on new drug targets, clinical trials and bureaucracy will remain the biggest bottleneck to fight cacner. 2. Repurposed drugs: the current cost of Phase 3 clinical trials only allows patentable solutions to be economically viable. It resonates that are probably many other treatments and potentially impactful drugs that won't be included in the Standard of Care as they haven't gone through phase 3 clinical trials.  3. Personalized medicine: organoids, digital twin, faster cycle from biopsy -> identifying targets -> creating customised solutions, such as mRNA vaccines, custom Antibody-Drug Conjugates (ADCs), and novel ways of triggering one's immune system.  4. Improving measurement: Currently, the standard PET-CT method does not allow weekly measurement of disease progression. Identifying a superior method to allow weekly measurement of progression could be instrumental in cutting down the time it takes to find a drug the body respond to. Anyone who can connect me to relevant companies will be widely appreciated
English
145
120
1.4K
103.2K
MikMi
MikMi@Mishkaida·
@MS_BASE44 @amsterdamski2 Checkout Novocure, an innovative company with a paradigm changing & proprietary medical device (Optune). FDA approved for Brain, Lung and (recently) Pancreatic Cancers.
English
1
0
1
1.3K
Maor Shlomo
Maor Shlomo@MS_BASE44·
Didn’t expect this level of reach Thank you everyone, I’ll be going over to the comments and my DMs in the next few days to respond, Thank you
Maor Shlomo@MS_BASE44

I'm looking to invest in cancer research and breakthrough treatment companies Cancer is humanity's worst enemy, and unfortunately, it's one of the few frontier problems i don't see getting solved in the next 2-3 years.  I'll be able to write checks up to a few million (usually up to a million).  I will work extremely hard to help the founders. I'll leverage my network as much as possible to overcome bureaucracies and help hunt down talent for every company I'm investing in. Things I'm particularly interested in:  1. Accelerating clinical trials: As AI gets smarter and allows novel hypotheses on new drug targets, clinical trials and bureaucracy will remain the biggest bottleneck to fight cacner. 2. Repurposed drugs: the current cost of Phase 3 clinical trials only allows patentable solutions to be economically viable. It resonates that are probably many other treatments and potentially impactful drugs that won't be included in the Standard of Care as they haven't gone through phase 3 clinical trials.  3. Personalized medicine: organoids, digital twin, faster cycle from biopsy -> identifying targets -> creating customised solutions, such as mRNA vaccines, custom Antibody-Drug Conjugates (ADCs), and novel ways of triggering one's immune system.  4. Improving measurement: Currently, the standard PET-CT method does not allow weekly measurement of disease progression. Identifying a superior method to allow weekly measurement of progression could be instrumental in cutting down the time it takes to find a drug the body respond to. Anyone who can connect me to relevant companies will be widely appreciated

English
8
3
105
10.5K
Maor Shlomo
Maor Shlomo@MS_BASE44·
I’m not sure this is done on purpose, or that there are “evil” corps steering us away from cheap cures. The reality is that getting a drug all the way from conception to a phase 3 clinical trial costs can cost > $1B. The only way to make this commercially viable is if the drug can be patented, so that it can later pay for the itself
English
0
0
4
328
Douglas Sweetman
Douglas Sweetman@Stockzorg·
@MS_BASE44 @exosome One thing you might try is funding some development efforts that the government, medical establishment and media is clearly trying to steer you away from. Like inexpensive existing substances that would not make Billions for the drug lords.
English
1
0
1
360
Maor Shlomo
Maor Shlomo@MS_BASE44·
Sid!  You’re an inspiration.  A close family member of mine is going through stage 4 cancer. I’ve been deep into searching for solutions for a while now, and your story gave me a lot of needed encouragement, as well as new directions (e.g. radioligand)  1. Completely agree with all that’s written in the article. I do feel like there are other fronts where technology can help accelerate trials and bring down costs. Patients recruitment is one of them  3. Yes. The more I learn the more I feel like this is the way.  I’ve also been in touch with Moufeed from Ranata, that I know you’re backing.    4. Interesting ! Going to do a deeper dive. I’m assuming it won’t say a lot re where the disease is growing, but it’s a start nonetheless
English
2
0
8
592
Sid Sijbrandij
Sid Sijbrandij@sytses·
Very cool! 1. Regarding accelerating clinical trials please see the ideas of @RuxandraTeslo for example writingruxandrabio.com/p/the-bureaucr… and the clinical trial abundance effort. 2. There are right to try laws in Montana and New Hampshire to let people try drugs after they are proven safe (phase I). 3. For sure! I'm taking a personalized mRNA and we're making custom ADCs, see sytse.com/cancer/ 4. ctDNA can be a faster way to measure disease, see osteosarc.com/timeline/ > MRD for my data
English
4
2
22
1.8K
Maor Shlomo
Maor Shlomo@MS_BASE44·
We're shipping now drastically faster. Here are things we released recently and haven’t announced yet: Superagent: Entity Automations - trigger flows like “when an order is created” with rich confirmation UI Reply to Messages - works across Web, Telegram & WhatsApp Better Memory Compliance - agents follow saved rules and facts more consistently Plugins Tab Redesign - cleaner layout with search & sorting Connector Access Control - set integrations to read-only or full access Platform: Model Selection - choose models inside base44 built-in llm Image Generation Upgrade - better quality, fallback chain, improved errors Generate Images in Builder, with real-time previews Social Content Engine - generate ready-to-post content across all major platforms Asset Library - centralized file management Profiles - public showcase for apps App Screenshots - auto-generated Unpublish Apps - take apps offline without losing data App Ownership Transfer - with workspace-level controls Per-Member Credit Limits - enterprise controls Workspace Secrets - secure API key management Guest Role - invite external collaborators Sidebar Navigation - the new home page looks amazing now. New Header - code view, fullscreen, domain controls Split Mode - flexible multi-view editing Domain Management tab redesign Command Palette (Cmd/Ctrl+K) for the builder! you have to try it! Debug Tool Logs - now includes backend logs Page Screenshots via Agents Smarter Automation Conditions Gmail Filtering Improvements Connectors: Massive expansion of integrations across Google, Microsoft, Slack, GitHub, Dropbox, Wix, and more OAuth connectors + user-of-user integrations Real-time webhook triggers (now always-on) Connector-powered automations Improved connector discovery (search & sorting) tons of small improvements, fixes, and polish across the platform More coming soon.
Maor Shlomo tweet media
English
19
11
81
6.6K
Maor Shlomo retweetledi
Base44
Base44@Base44·
Turn your app into ready-to-post content for LinkedIn, X, and more Open the Social Content tab, answer a couple of questions, and generate posts with images in seconds. Your content is tailored to your app and ready to publish, so you can focus on building instead of figuring out what to say. Refine and publish directly without leaving Base44.
English
14
11
107
9.4K
Maor Shlomo
Maor Shlomo@MS_BASE44·
Teachers weren't in our roadmap. 1.3 million education apps later, they're our biggest surprise. 870,000 of those builders are teachers, administrators, or students. It makes sense when you think about it. Teachers have the most specific, daily, unfixable problems. No edtech product fits the way their particular school runs. They've never had any way to build the exact tool they need. A teacher doesn't need Salesforce. He needs a parent communication app that works exactly the way his school does. A professor doesn't need a $10,000 LMS. She needs a course tracker that matches her grading system. A recent post by @tibo_maker made me think about it, and honestly, this might be the use case I'm most proud of.
Maor Shlomo tweet media
English
25
16
149
11.7K